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A Characteristic Subset of Psoriasis-Associated
Genes Is Induced by Oncostatin-M in Reconstituted
Epidermis
Alix Gazel1,2, Martin Rosdy2, Be´atrice Bertino2, Carine Tornier2, Florent Sahuc2 and
Miroslav Blumenberg1,3,4
The pathological manifestations of psoriasis are orchestrated by many secreted proteins, but only a handful,
tumor necrosis factor-alpha, IFN-g and IL-1, have been studied in great detail. Oncostatin-M (OsM) has also
been found in psoriatic skin and we hypothesized that it makes a unique and characteristic contribution to the
psoriatic processes. To define in-depth the molecular effects of OsM in epidermis, we used high-density
DNA microarrays for transcriptional profiling of OsM-treated human skin equivalents. We identified 374
unambiguously OsM-regulated genes, out of 22,000 probed. OsM suppressed the expression of the ‘‘classical’’
epidermal differentiation markers, but strongly and specifically induced the S100A proteins. Cytoskeletal and
complement proteins, proteases, and their inhibitors were also induced by OsM. Interestingly, a large set of
genes was induced by OsM at early time points but suppressed later; these genes are known regulatory targets
of IFN and thus provide a nexus between the OsM and IFN pathways. OsM induces IL-4 and suppresses the
T-helper 1-type and IL-1-responsive signals, potentially attenuating the psoriatic pathology. The data suggest
that OsM plays a unique role in psoriasis, different from all other, more thoroughly studied cytokines.
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INTRODUCTION
Psoriasis is a paradigm of inflammatory diseases of the skin,
which are mediated by white blood cells through an
orchestrated interplay of secreted cytokines and chemokines
that act on epidermal keratinocytes disrupting their differ-
entiation and causing hyperplasia (Nickoloff and Nestle,
2004; Bowcock and Krueger, 2005). The cytokines most
commonly studied in the context of psoriasis are tumor
necrosis factor-alpha (TNF-a), IFN-g, and IL-1 (Nickoloff,
1984; Groves et al., 1994); indeed, TNF-a-targeted therapies
show great promise for treatment of patients with psoriasis
(Gottlieb et al., 2005; Strober, 2005). Additionally, growth-
related cytokine alpha, IL-6, IL-8 macrophage inflammatory
protein 3-alpha, transforming growth factor-alpha, and its
analogs have been assigned prominent roles in the various
aspects of the pathology of psoriasis (Schon and Boehncke,
2005). However, Oncostatin-M (OsM) has received much
less attention, although it has been detected in the psoriatic
skin (Bonifati et al., 1998) and it may hamper the treatment of
the disease by inducing resistance to drugs (Dreuw et al.,
2005). OsM also plays a role in the initial phases of wound
healing (Goren et al., 2006). Subcutaneous injection of OSM
in mice causes an acute inflammatory reaction (Modur et al.,
1997). Keratoacanthomas and squamous cell carcinomas
express OsM and OsM is the major autocrine growth factor
for Kaposi sarcomas (Nair et al., 1992).
OsM was initially identified for its ability to inhibit
proliferation of tumor cell lines, but not healthy cells (Zarling
et al., 1986; Kligman and Thorne, 1990). It is produced by
activated T-lymphocytes, monocytes, and macrophages, and
perhaps hepatocytes and endothelial cells (Grant and Begley,
1999). OsM belongs to the IL-6/leukemia-inhibiting factor
cytokine family and mediates its activity through their common
gp130 receptor (Naar et al., 1991; Auguste et al., 1997; Grant
and Begley, 1999). The binding of OsM activates JAKs, receptor-
associated kinases that phosphorylate signal transducers and
activators of transcription (STATs), which, when phosphory-
lated, translocate to the nucleus and regulate transcription
(Darnell et al., 1994; Narazaki et al., 1994). Activation of JAK1
can activate the Raf-1/mitogen-activated protein kinase pathway
as well (Stancato et al., 1997; Ihn and Tamaki, 2000).
Because of the specific signaling pathways and molecular
responses to OsM in keratinocytes, we hypothesized that
among the panoply of symptoms and processes seen in
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psoriasis, OsM is responsible for a unique and characteristic
subset. Previously, we used high-density DNA microarrays
for transcriptional profiling in OsM-treated monolayer
cultures of human epidermal keratinocytes (Finelt et al.,
2005). We found that OsM strongly and specifically affects
the expression of many genes, in particular those involved
with innate immunity, angiogenesis, adhesion, motility,
tissue remodeling, cell cycle, and transcription. Secreted
cytokines and growth factors and their receptors, as well as
nuclear transcription factors, are primary targets of OsM
regulation, and these, in turn, effect the secondary changes.
The above studies, however, could not fully represent the
epidermal responses to OsM because keratinocyte mono-
layers do not fully recapitulate the multilayered differentia-
tion of the epidermis. Therefore, in this study we examined
the transcriptional effects of OsM in human skin equivalents
consisting of epidermal cells grown on air–liquid interface,
that is, stratified structures that completely recreate a
differentiating epidermis, including a fully formed stratum
corneum (Rosdy and Clauss, 1990; Gazel et al., 2003). Our
aim is to use skin equivalents made with healthy human cells
to create a reproducible model of psoriasis in vitro. Similar
skin reconstruction models with cells from psoriatic patients
have been used to replicate aspects of psoriatic phenotype
(Barker et al., 2004). We found that in the stratified skin
equivalents OsM, in addition to the already identified genes,
specifically suppresses ‘‘classical’’ differentiation markers,
involucrin, loricrin, and filaggrin, while strongly inducing the
S100A family of calcium-binding proteins.
RESULTS
At the beginning of the treatment, after 12 days of growth at
the air–liquid interface, the cultures are fully differentiated,
with a six to eight-cell-thick living layer, including a basal,
spinous, granular, and even a fully formed cornified layer
(Figure 1a). Between days 12 and 19, the extent of differen-
tiation in these cultures does not appreciably change. These
cultures do not senesce for at least another several weeks.
Therefore, during our experimental period, we see no pro-
nounced changes in the organotypic cultures. The cultures
are treated with OsM at three different times, on day 12 for
7 days, on day 17 for 48 hours, and on day 18 for 24 hours.
They are all harvested at the same time and processed
together to avoid technical variability.
Phenotypically, the OsM-treated and the -untreated skin
equivalents appear similar, although after 7 days of treatment
with OsM, the living layers are more preserved and there
is attendant reduction in cornified cells (Figure 1b). The
granular layer also appears different in OsM-treated cultures,
both morphologically and biochemically, with significantly
reduced expression of filaggrin (see Figure 4). Under appro-
priate conditions (M Rosdy, in preparation), even para-
keratosis can be observed (Figure 1c).
To determine which genes are regulated by OsM in
differentiating keratinocytes, we performed DNA microarray
analysis on skin equivalent samples that were treated with
OsM for 1 hour, 4, 24 and 48 hours, and 7 days, and on
their corresponding controls. We selected the differentially
expressed genes that were induced or suppressed at least
2-fold at two or more consecutive time points. We excluded
genes of unknown function and eliminated duplicates. Using
these stringent criteria, we found that of the approximately
12,000 genes present on the microarray chips, approximately
374 are regulated by OsM (Figure 2). Of these, 187 were
induced, 140 suppressed by OsM, while 47 genes were
both suppressed and induced, although at different time
points. The greatest number of genes, 265, was regulated at
the 48 hours time point.
The genes regulated by OsM in skin equivalents are listed
in Figure 3. A more detailed presentation of the regulated
genes is given in the Figure S1. We grouped the regulated
genes according to a hierarchical list of cellular functions for
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Figure 1. Morphological differences and parakeratosis in skin equivalents
after the treatment with OsM. (a) At the beginning of the treatment, days 12,
17, and 18, that is, 7, 2 days, and 1 day before harvesting, the organotypic
cultures are fully differentiated and have a functional stratum corneum.
(b) The samples were harvested simultaneously, after 19 days of growth at
air–liquid interface, which makes them identical in all aspects of growth,
except for the presence of OsM in the medium. (c) In certain treated cultures,
parakeratosis can be seen, with nuclei in the stratum corneum staining with
propidium iodide and keratin 17 induction detected using green immuno-
fluorescence. The dashed line represents the top of the artificial substrate
on which the basal cells are attached (original magnification200).
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Figure 2. The time course of gene regulation by OsM. The number of
induced and suppressed genes is plotted at each time point. The number
of suppressed genes at 1 hour time point may be underestimated because
the long half-life RNAs may not decay appreciably in the short time.
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aFigure 3. OsM-regulated genes in skin equivalents. The columns on the left show the maximum and minimum fold regulation at any time point, on a log 2 scale.
Gene symbols and Unigene comments are given next. The genes are grouped according to their functional categories marked with brackets. Shaded values
do not reach the cutoff of 2-fold regulation.
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bFigure 3. (continued)
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easy overview of the biological processes affected by OsM.
The higher-order groups include: (1) epidermal differentia-
tion, (2) cell fate, (3) structural proteins, (4) inflammation
and immunity, (5) signal transduction, (6) proteolysis, and
(7) metabolism. Within each, there are several more specific
categories. Although we attempted to categorize the regu-
lated genes with their most salient characteristics, we recog-
nize that the designations are somewhat arbitrary because
some genes belong to multiple categories (e.g. STAT1 and
STAT3 are transcription factors, but here are grouped with
inflammation/immunity category).
We were particularly interested in the specific effects
of OsMs on differentiating keratinocytes, and therefore
we compared the results in Figure 3 with the published
list of OsM-regulated genes in keratinocyte monolayer
cultures (Figure S2; Finelt et al., 2005). We find that, in
general, OsM regulates similar sets of genes in mono-
layers and in stratified cultures, provided the genes of
interest are expressed in the monolayers. For example, the
membrane proteins group contains roughly equal numbers of
induced and suppressed genes and most of them are
expressed both in monolayer cultures and in stratified skin
equivalents. Within this group, the induced genes tend to
be induced both in stratified skin equivalents and in the
monolayer cultures, and the parallel holds for the suppressed
genes as well (Figure S2).
In contrast, the epidermal differentiation markers are
generally not expressed in monolayer cultures (Figure S3).
In this functional category, we find a complex and intriguing
result. Half of the epidermal differentiation marker genes are
induced, whereas half are suppressed by OsM (Figure S3).
Upon closer look, the markers divide into two clearly distinct
categories: the S100A proteins are induced, whereas the
‘‘classical’’ markers, loricrin, filaggrin, involucrin, and late
envelope proteins xp32 and xp33, are suppressed. The
suppression of these markers may correlate with the inhi-
bition of cornification by OsM, as shown in Figure 1. Many of
the regulated genes are located in the epidermal differentia-
tion complex on chromosome 1q21 (Zhao and Elder, 1997).
Similarly suppressed are corneodesmosin, envoplakin, and
many enzymes of lipid and steroid metabolism, genes that are
specifically induced during epidermal differentiation, but are
not encoded in the epidermal differentiation complex (Elias,
2005). The overall conclusion from these results is that
OsM suppresses the expression of epidermal differentiation
markers, except for the S100A class.
Cell proliferation is among the important processes
regulated by extracellular influences and therefore we speci-
fically examined the associated functional categories, includ-
ing cell cycle and DNA replication. These functional
categories are usually co-regulated and strong proliferative
and antiproliferative signals can synchronously induce or
suppress a large set of these genes (Banno et al., 2003). We
compared the OsM-regulated genes to those affected by
IFN-g, a strong suppressor of proliferation (Banno et al.,
2003), or TNF-a, a mild enhancer (Banno et al., 2004). No
clear trends were seen; OsM does not regulate many genes in
these categories and the numbers of induced and suppressed
genes is balanced. The data suggest that OsM does not affect
keratinocyte proliferation. Similarly, only a few apoptosis-
associated genes are regulated by OsM and, while more
genes are induced than suppressed, apoptosis seems not to be
clearly affected by OsM. We note, however, that the CFLAR,
an essential antiapoptotic gene, was induced by OsM, which
may inhibit apoptosis in keratinocytes. We conclude that
OsM is not a direct regulator of keratinocyte cell fate in the
epidermis.
Several structural proteins, both extracellular and cyto-
plasmic, are regulated by OsM. Although not many cyto-
skeletal proteins are affected, OsM strongly induced adhesion
proteins. In particular, cadherins and basal cell-specific
desmosomal proteins desmogleins 2, desmocolin 2, and
desmocolin 3 are induced (Yin et al., 2004). Furthermore,
several extracellular matrix proteins are induced. Conversely,
very few of the genes in these functional categories are
suppressed by OsM. Apparently, OsM boosts the cellular
adhesion of the epidermal basal layer by inducing the
production of the components of the desmosomal and
adherens junctions, and their extracellular counterparts.
Importantly, a large proportion of genes associated with
inflammation and immunity are regulated by OsM (Figure 3).
Three complement proteins are induced, providing a
hitherto unrecognized link between the complement and
OsM. Components of the IL-1 pathway are suppressed by
OsM while annexins are induced. The T-helper (Th)2-asso-
ciated cytokine IL-4 and its receptor IL-4R are induced by
OsM, whereas IL-18, an inducer of INF-g, is suppressed.
STAT3, OsM-specific responder transcription factor, is
induced, whereas STAT1, the primary IFN-g responder, is
suppressed. The overall effect of OsM may be to quiet
down the inflammatory and immune responses in psoriatic
epidermis.
Among the signal-transduction proteins affected by
OsM, we found several protein kinases and phosphatases,
G-protein-coupled receptors and G-regulated proteins, as
well as transcription factors. Although more genes are
induced than suppressed, the regulated proteins do not
point to a specific pathway or process. For example, mitogen-
activated protein kinase and dual-specificity phosphatase
family kinases and phosphatases are not regulated by OsM
and many of the well-characterized regulated transcription
factors, for example, the NF-kB, activator protein 1 and the
nuclear receptor family, are scarcely represented among the
regulated genes. These results are in stark contrast with those
we saw in TNF-a- or IFN-g- treated keratinocytes, where the
signal-transduction proteins are among the most conspicuous
regulated functional categories (Banno et al., 2003, 2004).
Prominent among the OsM-regulated genes are those
encoding proteases and their inhibitors. Proteases and pepti-
dases are, in general, suppressed, whereas proteolysis
inhibitors of the SERPIN family are induced. Matrix metallo-
proteinase 1, interstitial collagenase, is induced, whereas
matrix metalloproteinase 9, 92 kD gelatinase, is suppressed.
Several ubiquitin pathway proteins are induced, with none
suppressed, suggesting that certain intracellular substrates are
specifically targeted for degradation through the ubiquitin
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pathway by OsM. Overall, proteolysis is one of the processes
significantly altered by OsM in skin equivalents.
Metabolic pathways affected by OsM include energy-
producing enzymes. The carbohydrate metabolism enzymes
are induced, whereas the amino-acid metabolism ones
are suppressed. Mitochondrial and detoxifying proteins are
suppressed. Many transporter proteins are regulated by OsM;
approximately similar numbers are induced and suppressed.
We noticed that a relatively large group of genes was
found to be induced by OsM at the early time points, 1 hour
and 4 hours post-treatment, and then suppressed at the late
time points, 2 and 7 days post-treatment (Figure S4). To
investigate this phenomenon more closely, we identified the
34 genes with a similar expression pattern (Figure S4). Most of
these show suppression at the 24 hour time point already. For
8/34, the function is not known and their only ontological
category is that they are regulated by IFN-g. For the
remainder, careful individual analysis showed that many
are known to be regulated by IFN (MX1, MAD2L1, IRS1,
IGFBP2, ANGPT1, IFI27, STAT1, and TRIM22), whereas
others (e.g., C1D, POLA, PLOD2, LRMP, GPR19, LSM6,
BST2, SEMA3C, LAMP3, POLR3F, SLC26A1, and SLC16A5)
were not known to be IFN-regulated; we predict that the
regulation by IFN-g will be established for these genes as
well. These genes identify a parallel between the OsM and
IFN signaling. Curiously, two proteins associated with
melanocytes are in this category, TYRP1 and SILV (Figure
S4). The significance of this phenomenon is at present
unknown, but it may reflect the presence of a small number
of melanocytes in our cultures. In contrast, the few genes
suppressed early and induced late by OsM are not known
to be regulated by IFN. The only exception is heat-shock
protein A1B, which was shown to be suppressed by IFN-g
(Saile et al., 2004). The reciprocal regulation of this gene
reinforces the connection between the OsM and IFN
signaling pathways.
To cross-reference the OsM-regulated genes with genes
regulated under other circumstances, we used the L2L set of
comparison programs. The lists of OsM-regulated genes were
compared with the gene ontology categories of Biological
Process, Molecular function, and Cellular Component, as
well as with a set of lists of regulated genes in the L2L
database (Figure S5). These analyses can lead to under-
standing of the biological processes and functions affected
by OsM.
The biological processes induced by OsM at the 1 hour
time point include genes responsible for the immune,
inflammatory, and defensive responses to pathogens and
stress (Figure S5). Similar biological processes are induced
by OsM when all time points are analyzed in aggregate, with
the addition of the genes associated with the responses
to wounding and with chemotaxis. Interestingly, OsM
suppressed the genes that belong to the NF-kB signal trans-
duction at the 1 hour time point. At later time points, the
biological processes concerning steroid and lipid metabolism
are suppressed, these are differentiation-associated processes.
The genes induced by OsM at early, and suppressed at late
time points also identify the associated biological processes
with very high statistical probability, and these processes
include JAK-STAT signaling cascade. These results further
corroborate the nexus between the IFN signaling and OsM
signaling.
The molecular functions associated with the OsM-induced
genes concern transcription and cytoskeletal proteins, while
protein degradation seems suppressed especially at the early
time points (Figure S5). Antiviral responses comprise the most
certain molecular function of the induced/suppressed genes,
paralleling the IFN-responsive molecular functions.
The cellular components induced by OsM include
extracellular and intermediate filament-associated proteins,
while the suppressed ones include junctional proteins,
perhaps in conjunction with the increased taxis and motility
of the OsM-treated cells (Figure S5).
We compared the lists of OsM-regulated genes with a
large collection of lists of genes regulated by other agents
(Newman and Weiner, 2005). Although the induced and
suppressed genes did not reach high probability of related-
ness to any gene list tested, the genes described in Figure S4,
that is, those induced early and suppressed late, did achieve
very high P-values (Figure S5). Specifically, the highest
probability of relatedness, P¼41022, was found between
these genes and the genes induced by the ectopic expression
of IRF3 (a.k.a. NF90) (Krasnoselskaya-Riz et al., 2002). In
addition, the IFN-induced and transforming growth factor-
beta- and TNF-a-induced genes are significantly related to the
up-then-down OsM-regulated genes (Figure S5).
To determine whether the OsM-regulated genes have an
overabundance of a particular transcription factor binding
site in the DNAs of their promoters, we used the oPOSSUM
set of programs (Ho Sui et al., 2005). We did not find a
highly probable set of binding sites, and SPI-B and cEBP
sites barely reached statistical significance for the set of all
OsM-regulated genes, while Irf-1 barely reached statistical
significance for the genes induced at 1 hour and 4 hours post-
OsM treatment (Figure S6). We note that the most current
version of oPOSSUM does not list STAT binding sites.
To verify the effects of OsM in skin equivalents, we
focused on the induction of the S100 proteins by OsM
because of their association with psoriasis. The quanti-
tative real-time reverse transcription (RT)-PCR of S100A7
(psoriasin 1) and S100A12 (calgranulin C) mRNA shows time-
dependent increase for both genes, confirming the microarray
results described above (Figure 4). The increase of the
psoriasin 1 mRNA during the OSM treatment kinetics was
steady and smooth, whereas the calgranulin C mRNA was
increased to extraordinarily high levels after 7 days of the
OSM treatment. In both cases, the 7 days OSM treatment led
to the strongest mRNA induction: 40.6 times for psoriasin 1
and 46.8 times for calgranulin C. The induction was confir-
med at the protein level, using Western blotting (Figure 4).
Whereas phenotypically, the treated and the untreated
samples appeared very similar, OsM strongly induced the
expression of S100A7 in the treated samples (Figure 4).
Importantly, while S100A7 was induced to a high level in the
granular layer, the induction of keratin 17 begins, and seems
the strongest in the spinous layer. These data not only confirm
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our findings in microarray and RT-PCR analysis at the protein
level but also demonstrate that the induction of the epidermal
genes in skin equivalents occurs in the appropriate layer of
the epidermis.
DISCUSSION
The results presented here demonstrate that, indeed, in the
complex orchestration of the psoriasiform phenotype, the
OsM strikes a specialized, important, and unique note.
Specifically, OsM inhibits the expression of ‘‘classical’’
epidermal differentiation markers, while simultaneously
inducing the expression of psoriasin and other S100A
calcium-binding signaling proteins. In keratinocytes, OsM
primarily affect proteolysis, the differentiation process, the
cytoskeleton, and the adhesion structures. The effects of OsM
are thus different from the effects of IFN-g, which primarily
stimulates an antiviral state, induces production of cytokines
and chemokines and inhibits keratinocyte proliferation. They
are also different from the effects of TNF-a, which also
induces the expression of secreted signaling proteins, induces
apoptotic proteins, and cytoskeletal components associated
with increased motility. Furthermore, we show that the
skin equivalents, with their three-dimensional architecture
and faithful reproduction of epidermal differentiation process,
represent an excellent model to study the psoriasiform
changes caused by OsM and, presumably, other growth
factors and cytokines.
OsM seems to have both proinflammatory and anti-
inflammatory properties in skin equivalents. The proinflam-
matory effects of OsM are stimulated in part through the
induction of the S100A proteins, which can act as secreted
signaling messengers in inflammation, in tumors and other
pathological conditions (Roth et al., 2003; Cross et al., 2005;
Hermani et al., 2006). We were particularly impressed with
the extremely high induction of the S100A proteins by OsM;
the over 100-fold induction of any gene by any extracellular
agent in keratinocytes is, to our knowledge, unprecedented.
We note that the values in Figure 3 are on log 2 scale; the
actual maximum fold induction for S100A7 and S100A12 are
144- and 137-fold, respectively. Because the induction of
S100A8 and S100A9 pair was found to be among the earliest
molecular changes in an animal model resembling psoriatic
eruptions (Zenz et al., 2005), and because OsM causes such
drastic induction of the S100A proteins, it is possible that OsM
plays a much more important role in the induction of S100A
proteins in the psoriatic phenotype than IL-1 and TNF-a.
The S100A proteins activate the NF-kB and mitogen-
activated protein kinase pathways; they are chemotactic and
proinflammatory, and play a role in angiogenesis, and
squamous and basal cell carcinomas (Roth et al., 2003;
Semov et al., 2005; Hermani et al., 2006). The S100A
proteins are encoded at the epidermal differentiation com-
plex, on chromosome 1q21; they have been found incorpo-
rated into cornified envelopes and associated with epidermal
differentiation (Robinson et al., 1997). The expression of
S100A genes is associated with other processes besides
epidermal differentiation; they serve different functions and
have a different regulatory set of influences (Broome et al.,
2003; Eckert et al., 2004; Cross et al., 2005; Jackson et al.,
2005). Thus, the borders of the epidermal differentiation
locus proper may not include the S100A genes. However,
the epidermal differentiation-specific regulatory circuits of
epidermal differentiation complex may influence the neigh-
boring genes (Elder and Zhao, 2002). The S100A genes may
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Figure 4. S100A7 is induced by OsM in skin equivalents. (a) Immunohistological detection of S100A7 (psoriasin) and keratin 17 in skin equivalents after
the treatment with OsM. The expression of filaggrin is reduced (original magnification200). (b) RT-PCR showing S100A7 and S100A12 mRNAs are induced
by OsM in skin equivalents. The numbers show fold increase in the OsM-treated tissue, over the untreated controls. (c) Western blots confirm the induction
of S100A7 by OsM at the protein level.
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use such circuits in the epidermis to limit their expression to
the differentiating layers.
The anti-inflammatory effects of OsM include the suppres-
sion of Th1-type signaling molecules and induction of IL-4,
a Th2-type cytokine. Psoriasis is a distinctly Th1-associated
disease (Lew et al., 2004) and by inducing a Th2-type
cytokine OsM may be acting to inhibit the Th1 psoriatic
processes. Furthermore, OsM suppresses the expression of
STAT1, transcription factor specifically responsive to IFN-g, a
Th1-type cytokine, while inducing the expression of STAT3,
the OsM-responsive one. In addition, by suppressing IL-1
signals, OsM may be suppressing the proinflammatory
psoriatic processes. The combined effects of OsM may
reduce the severity of psoriasis, an interesting hypothesis
that deserves further exploration.
Particularly intriguing is the discovery of the large set of
genes that are induced at the early but suppressed at the later
time points after the OsM treatment. Although the differences
between the early and late effects may be due to the changes
inherent in organotypic culture, it is more likely that these
represent a nexus between the IFN-g and the OsM signaling
pathways. The nexus may be owing to a partial overlap of the
STAT1- and STAT3-targeted genes. However, the genes with
this particular regulatory pattern also overlap a set of genes
induced by NF90, a double-stranded RNA-binding protein
that mediates a subset of IFN-g responses (Krasnoselskaya-Riz
et al., 2002). Therefore, OsM may have an intriguing and so
far unexplored role in viral infections; this contention is
strengthened by the known association of OsM with Kaposi’s
sarcomas (Nair et al., 1992).
Importantly, while the analysis of the keratinocytes cul-
tured in monolayers yielded a trove of information regarding
the molecular and biological effects of OsMs, it is clear that
certain important aspects of OsM biology in the epidermis
could not be seen in the undifferentiating cultures. Therefore,
skin equivalents, such as the ones used here, represent a
major improvement in our ability to reproduce in vitro a fuller
spectrum of in vivo epidermal responses to external
influences.
MATERIALS AND METHODS
Production and maintenance of skin equivalents
The reconstituted human epidermis (SkinEthic Laboratories, Nice,
France) consists of a fully differentiated three-dimensional multi-
layered keratinocyte structure grown on the air–liquid interface at
371C, 5% CO2, and saturated humidity for 19 days on modified
chemically defined medium (MCDB) 153 supplemented with 1 ng/
ml EGF, 0.4 mg/ml hydrocortisone, and 5 mg/ml insulin (growth
medium) (Rosdy and Clauss, 1990; Rosdy et al., 1997; Bernard et al.,
2000). Samples for RT-PCR, Western blots, and histology sections
and staining originated from several different skin donors. All cells
were expanded and treated according to the SkinEthic quality-
controlled production procedures.
OsM tissue treatment
Growth medium was supplemented with 5 ng/ml OsM (R&D
Systems, Abingdon, UK) for 1 hour, 4, 24, and 48 hours, and 7 days
before harvesting. Note that the 24, 48, and 72 hours samples were
treated on days 18, 17, and 12 of culture, respectively. At day 19,
all tissues were harvested for microarray analysis, immunohisto-
chemical studies, Western blotting, and quantitative real-time
RT-PCR analysis. We chose this treatment because it allowed us to
harvest all samples on the same day, that is, at the exactly the same
stage of growth, differentiation, and cornification. The untreated
tissues were used as negative controls.
Preparation and hybridization of probes
The inserts were placed on 4 ml dispase II (Roche, Meylan, France)
in a 100 mm Petri dish at room temperature. After 3 minutes,
the epidermal tissues were removed from the polycarbonate filter
inserts with fine RNase-free forceps. RNA was isolated using the
Qiagen kit (Qiagen, Chatsworth, CA) according to the manu-
facturer’s instructions. Approximately 8mg of total RNA was
reverse-transcribed, amplified, and labeled as described (Li et al.,
2001;Banno et al., 2004). The labeled cRNA was hybridized to
HGU95Av2 arrays (Affymetrix, Santa Clara, CA) with the capacity
to display transcript levels of approximately 12,000 human
genes. Arrays were washed, stained with anti-biotin streptavidin–
phycoerythrin-labeled antibody, and scanned using the Gene Array
Scanner system (Hewlett-Packard, Palo Alto, CA), as described
by Affymetrix.
Gene array data analysis
Intensity values were obtained using GCOS Microarray Suite version
5.0. (Affymetrix), and normalized by setting the overall signal for
each array to 500 arbitrary units. To eliminate genes not expressed in
keratinocytes, or genes expressed at such low levels that their
measurements were unreliable, we first determined the signal
intensity value that is 1 SD above average for all genes scored as
‘‘absent’’ in the samples, specifically 150 U. We removed from
analysis all genes with expression levels below 150 in every sample
and genes not scored as ‘‘present’’ in at least one of the 10 samples.
Affymetrix’ GCOS programs was used to derive scatter-plots,
perform the t-test and the Mann–Whitney test, and calculate fold
change in preliminary data analyses.
Genes were considered regulated if their expression levels
differed 2-fold or more between control and treated samples, or if
they were deemed increased or decreased according to the GCOS
criteria. To reduce the number of false positives, we used very strict
selection criteria and only retained for analysis the genes that are
regulated in the same direction in at least two consecutive time
points. As a result, the consecutive time points serve as pseudo-
duplicates. The regulated genes were functionally classified accord-
ing to an extensive gene annotation table describing the molecular
function and biological category of the genes present on the chip.
The table is based on the Gene Ontology Consortium http://cgap.
nci.nih.gov/Genes/GOBrowser.
The list of Ch1q21 genes in the epidermal differentiation locus
was obtained from National Center for Biological Information Map
Viewer http://www.ncbi.nlm.nih.gov/mapview. To compare the lists
of OsM-regulated genes with lists of gene ontology annotated genes,
we used the L2L microarray analysis tool, http://depts.washington.
edu/l2l (Newman and Weiner, 2005). We used the 2005-06-15
version. The transcription factor binding sites were searched using
oPOSSUM tool http://www.cisreg.ca/cgi-bin/oPOSSUM/opossum
(Ho Sui et al., 2005).
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The data are deposited with the GEO, http://www.ncbi.nlm.nih.
gov/geo/, under the access number GSE2822.
Quantitative real-time RT-PCR analysis
After dispase treatment (see above), total RNAs were extracted from
three epidermal tissues using Trizol Reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions, and then treated
with Turbo Deoxyribonuclease I (Turbo DNA-free, Ambion, Austin,
TX). Purified RNAs (1.5 mg) were incubated in a solution containing
50 ng of random hexanucleotides, 500 ng Oligo(dT)12–18 and 200 U
of SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA) in a
final volume of 20 ml at 421C, for 2 hours to synthesize the cDNAs.
Two units of E. coli RNAse H (Invitrogen, Carlsbad, CA) were added,
and samples were incubated 20 minutes at 371C.
S100A7 and S100A12 expression analysis was performed
by quantitative real-time PCR procedure using an ABY Prism 7700
real-time PCR machine (Perkin-Elmer, Boston, MA). The primer
sequences were as follows: S100A7-JID, GenBank NM002963, FP:
50-CCCAACTTCCTTAGTGCCTGTG, RP: 50-AAGACGTCGGCGAG
GTAATTT (Ebihara et al., 2005); S100A7-EJP, FP: 50-CTTCCTTAGTG
CCTGTGACAAAAA; RP: 50-AAGGACAGAAACTCAGAAAAATCAA
TCT (Franssen et al., 2005); S100A12, GenBank NM005621, FP: 50-
CACTGCTGGCTTTTTGCTGTAG, RP: 50-TTAACCCCTCAATGCAC
AGGA (Ebihara et al., 2005); and TBP, FP: 50-ACCCTTCACCAATGA
CTCCTATG, RP: 50-ATGATGACTGCAGCAAATCGC (Bezy et al.,
2005). The optimal primer concentration (300, 600, 900 nM) for A7
and A12 genes was chosen to achieve maximum amplification and
minimum nonspecific amplification. All primers were obtained from
Eurogentec SA (Seraing, Belgium). The real-time PCR assays were
performed using 1.33 ml of first-strand cDNA as template and 300 nM
of paired primers. Reactions were performed according to the
manufacturer’s instructions by using SYBR green PCR Master Mix
(Perkin-Elmer, Boston, MA). The expression of S100 calcium-binding
protein A7 and A12 was normalized to the expression to TBP.
Immunohistology
Epidermal tissues were fixed in 10% formalin neutral buffered
solution and embedded in paraffin. Four micrometer vertical sections
were stained with hematoxylin/eosin for standard histology. For
immunohistology, antigen retrieval was performed on de-paraffi-
nized sections by cooking in citrate buffer (pH 6.0). Then, sections
were incubated with primary monoclonal antibodies for psoriasin
(psoriasin/HID-5 clone 47C1068, Imgenex, San Diego, CA) or
keratin 17 (Keratin 17 clone E3), filaggrin (clone FLG01, Neomarkers,
Fremont, CA), for 1 hour at room temperature. Subsequently, the
sections were stained with horseradish peroxidase-conjugated
secondary antibody for psoriasin, whereas for keratin 17 the sections
were stained with Ultravision LP System (HRP polymer, Neomarkers,
Freemont, CA), visualized with 30-diaminobenzodine tetrahydro-
chloride chromogen, and counterstained with hematoxylin.
For immunofluorescence, epidermal cultures were frozen
directly at 801C. Before being cut, they were embedded in
octamer motif-binding compound (Miles, Elkhart, IN). Vertical
sections were air-dried, rinsed in phosphate-buffered saline and
incubated with a primary monoclonal antibody for keratin 17 clone
E3, (Dako, Denmark), then with a fluorescent secondary antibody
(Dako, Denmark) and counterstained with a propidium iodide
solution (50 mg/ml) (Sigma, St Louis, MO).
Western blotting
After dispase treatment (as above), three epidermal tissues of
0.5 cm2. for each time point or control were transferred to a 1.5 ml
microtube containing 1 ml lysis buffer (20 mM Tris (pH 7.4), 150 mM
NaCl, 1 ml EDTA 1% NP-40, and 1% protease inhibitor cocktail).
After 30 minutes of incubation on ice, the samples were sonicated
and centrifuged at 10.000 g for 10 minutes. Protein concentration
was determined using Bradford Bio-Rad protein assay (Bio-Rad,
Hercules, CA). Five micrograms of proteins were electrophoresed in
15% SDS-PAGE, and then transferred to nitrocellulose membrane
(Bio-Rad, Hercules, CA).
The membrane was blocked for 30 minutes with phosphate-
buffered saline (pH 7.2) solution, containing 0.05% Tween 20 and
5% low-fat milk, and then incubated overnight at 41C with primary
antibody (mAb to psoriasin, HID-5 clone 47C1068, Imgenex, San
Diego, CA or polyclonal antibody to calgranulin C, C20, Santa Cruz
Biotechnology, Santa Cruz, CA). After phosphate-buffered saline
washing, the membrane was incubated at room temperature for
1 hour with horseradish peroxidase-conjugated secondary antibody
for psoriasin (Sigma, St Louis, MO). Visualization was performed
using 30-diaminobenzodine tetrahydrochloride as the chromogen.
CONFLICT OF INTEREST
Drs Rosdy, Bertino, Tornier, Mas, and Sahuc are employed by Skinethic; the
skin equivalents used in this study were produced by Skinethic and were
provided grants for experimentation.
ACKNOWLEDGMENTS
Our research is supported in part by a grant from DebRA-UK Foundation with
additional support from DebRA of America.
SUPPLEMENTARY MATERIAL
Figure S1. OsM-regulated genes in skin equivalents.
Figure S2. Comparison of the regulated genes by OsM in skin equivalents and
in monolayer cultures.
Figure S3. The epidermal differentiation complex on chromosome 1.
Figure S4. OsM-regulated genes induced at the early, and suppressed at the
late time points.
Figure S5. Comparison of the lists of OsM-regulated genes with Gene
Ontology categories and specific lists of genes identified in other systems.
Figure S6. Transcription factor binding sites in the promoters of the OsM-
regulated genes.
REFERENCES
Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-Barthelaix A
et al. (1997) Signaling of type II oncostatin M receptor. J Biol Chem
272:15760–4
Banno T, Adachi M, Mukkamala L, Blumenberg M (2003) Unique
keratinocyte-specific effects of interferon-gamma that protect skin
from viruses, identified using transcriptional profiling. Antiviral Ther 8:
541–54
Banno T, Gazel A, Blumenberg M, Adachi M, Mukkamala L (2004)
Effects of tumor necrosis factor-a (TNFa) in epidermal keratinocytes
revealed using global transcriptional profiling. J Biol Chem 279:
32633–42
Barker CL, McHale MT, Gillies AK, Waller J, Pearce DM, Osborne J et al.
(2004) The development and characterization of an in vitro model of
psoriasis. J Invest Dermatol 123:892–991
Bernard FX, Barrault C, Deguercy A, De Wever B, Rosdy M (2000)
Development of a highly sensitive in vitro phototoxicity assay using
the SkinEthic reconstructed human epidermis. Cell Biol Toxicol
16:391–400
www.jidonline.org 2655
A Gazel et al.
Effects of OsM in Skin Equivalents
Bezy O, Elabd C, Cochet O, Petersen RK, Kristiansen K, Dani C et al. (2005)
Delta-interacting protein A, a new inhibitory partner of CCAAT/
enhancer-binding protein beta, implicated in adipocyte differentiation.
J Biol Chem 280:11432–8
Bonifati C, Mussi A, D’Auria L, Carducci M, Trento E, Cordiali-Fei P et al.
(1998) Spontaneous release of leukemia inhibitory factor and oncostatin-
M is increased in supernatants of short-term organ cultures from lesional
psoriatic skin. Arch Dermatol Res 290:9–13
Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics
of psoriasis. Nat Rev Immunol 5:699–711
Broome AM, Ryan D, Eckert RL (2003) S100 protein subcellular localization
during epidermal differentiation and psoriasis. J Histochem Cytochem
51:675–85
Cross SS, Hamdy FC, Deloulme JC, Rehman I (2005) Expression of S100
proteins in normal human tissues and common cancers using tissue
microarrays: S100A6, S100A8, S100A9 and S100A11 are all over-
expressed in common cancers. Histopathology 46:256–69
Darnell J Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional
activation in response to IFNs and other extracellular signaling proteins.
Science 264:1415–21
Dreuw A, Hermanns HM, Heise R, Joussen S, Rodriguez F, Marquardt Y et al.
(2005) Interleukin-6-type cytokines upregulate expression of multidrug
resistance-associated proteins in NHEK and dermal fibroblasts. J Invest
Dermatol 124:28–37
Ebihara T, Endo R, Kikuta H, Ishiguro N, Ma X, Shimazu M et al. (2005)
Differential gene expression of S100 protein family in leukocytes
from patients with Kawasaki disease. Eur J Pediatr 164:427–31 (E-pub
ahead of print) 19 Apr 2005
Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K (2004) S100
proteins in the epidermis. J Invest Dermatol 123:23–33
Elder JT, Zhao X (2002) Evidence for local control of gene expression in the
epidermal differentiation complex. Exp Dermatol 11:406–12
Elias PM (2005) Stratum corneum defensive functions: an integrated view.
J Invest Dermatol 125:183–200
Finelt N, Gazel A, Gorelick S, Blumenberg M (2005) Transcriptional
responses of human epidermal keratinocytes to Oncostatin-M. Cytokine
31:305–13
Franssen ME, Zeeuwen PL, Vierwinden G, van de Kerkhof PC, Schalkwijk J,
van Erp PE (2005) Phenotypical and functional differences in germinative
subpopulations derived from normal and psoriatic epidermis. J Invest
Dermatol 124:373–83
Gazel A, Ramphal P, Rosdy M, De Wever B, Tornier C, Hosein N et al. (2003)
Transcriptional profiling of epidermal keratinocytes: comparison of
genes expressed in skin, cultured keratinocytes, and reconstituted
epidermis, using large DNA microarrays. J Invest Dermatol 121:1459–68
Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA et al.
(2005) TNF inhibition rapidly down-regulates multiple proinflammatory
pathways in psoriasis plaques. J Immunol 175:2721–9
Grant SL, Begley CG (1999) The oncostatin M signalling pathway: reversing
the neoplastic phenotype? Mol Med Today 5:406–12
Goren I, Kampfer H, Muller E, Schiefelbein D, Pfeilschifter J, Frank S (2006)
Oncostatin M expression is functionally connected to neutrophils in the
early inflammatory phase of skin repair: Implications for normal and
diabetes-impaired wounds. J Invest Dermatol 126:628–37
Groves RW, Sherman L, Mizutani H, Dower SK, Kupper TS (1994) Detection
of interleukin-1 receptors in human epidermis. Induction of the type II
receptor after organ culture and in psoriasis. Am J Pathol 145:1048–56
Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D (2006) S100A8
and S100A9 activate MAP kinase and NF-kappaB signaling pathways
and trigger translocation of RAGE in human prostate cancer cells. Exp
Cell Res 312:184–97
Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP et al.
(2005) oPOSSUM: identification of over-represented transcription factor
binding sites in co-expressed genes. Nucleic Acids Res 33:3154–64
Ihn H, Tamaki K (2000) Oncostatin M stimulates the growth of dermal
fibroblasts via a mitogen-activated protein kinase-dependent pathway.
J Immunol 165:2149–55
Jackson B, Tilli CL, Hardman M, Avilion A, Macleod M, Ashcroft G
et al. (2005) Late cornified envelope family in differentiating epithelia
– response to calcium and ultraviolet irradiation. J Invest Dermatol 124:
1062–70
Kligman AM, Thorne EG (1990) Topical therapy of actinic keratoses with
tretinoin. In: Retinoids in cutaneous malignancy (Marks R, ed) London:
Blackwell Scientific Publisher, 67–73
Krasnoselskaya-Riz I, Spruill A, Chen YW, Schuster D, Teslovich T, Baker C
et al. (2002) Nuclear factor 90 mediates activation of the cellular
antiviral expression cascade. AIDS Res Hum Retroviruses 18:591–604
Lew W, Bowcock AM, Krueger JG (2004) Psoriasis vulgaris: cutaneous
lymphoid tissue supports T-cell activation and ‘‘Type 1’’ inflammatory
gene expression. Trends Immunol 25:295–305
Li D, Turi TG, Schuck A, Freedberg IM, Khitrov G, Blumenberg M (2001) Rays
and arrays: the transcriptional program in the response of human
epidermal keratinocytes to UVB illumination. FASEB J 15:2533–5
Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA
et al. (1997) Oncostatin M is a proinflammatory mediator. In vivo effects
correlate with endothelial cell expression of inflammatory cytokines and
adhesion molecules. J Clin Invest 100:158–68
Naar AM, Boutin JM, Lipkin SM, Yu VC, Holloway JM, Glass CK et al. (1991)
The orientation and spacing of core DNA-binding motifs dictate selective
transcriptional responses to three nuclear receptors. Cell 65:1267–79
Nair BC, DeVico AL, Nakamura S, Copeland TD, Chen Y, Patel A et al. (1992)
Identification of a major growth factor for AIDS-Kaposi’s sarcoma cells as
oncostatin M. Science 255:1430–2
Narazaki M, Witthuhn BA, Yoshida K, Silvennoinen O, Yasukawa K, Ihle JN
et al. (1994) Activation of JAK2 kinase mediated by the interleukin 6
signal transducer gp130. Proc Natl Acad Sci USA 91:2285–9
Newman JC, Weiner AM (2005) L2L: a simple tool for discovering the hidden
significance in microarray expression data. Genome Biol 6:R81 (E-pub
ahead of print) 31 Aug 2005
Nickoloff BJ (1984) Lymphocyte–keratinocyte interactions mediated through
interferon. New observations relevant to psoriasis. Cutis 34:445–6
Nickoloff BJ, Nestle FO (2004) Recent insights into the immunopathogenesis
of psoriasis provide new therapeutic opportunities. J Clin Invest
113:1664–75
Robinson NA, Lapic S, Welter JF, Eckert RL (1997) S100A11, S100A10,
annexin I, desmosomal proteins, small proline-rich proteins, plasmino-
gen activator inhibitor-2, and involucrin are components of the cornified
envelope of cultured human epidermal keratinocytes. J Biol Chem
272:12035–46
Rosdy M, Bertino B, Butet V, Gibbs S, Ponec M, Darmon M (1997) Retinoic
acid inhibits epidermal differentiation when applied topically on the
stratum corneum of epidermis formed in vitro by human keratinocytes
grown on defined medium. In Vitro Mol Toxicol 11:39–47
Rosdy M, Clauss LC (1990) Terminal epidermal differentiation of human
keratinocytes grown in chemically defined medium on inert filter
substrates at the air–liquid interface. J Invest Dermatol 95:409–14
Roth J, Vogl T, Sorg C, Sunderkotter C (2003) Phagocyte-specific S100
proteins: a novel group of proinflammatory molecules. Trends Immunol
24:155–8
Saile B, Eisenbach C, Dudas J, El-Armouche H, Ramadori G (2004) Interferon-
gamma acts proapoptotic on hepatic stellate cells (HSC) and abrogates
the antiapoptotic effect of interferon-alpha by an HSP70-dependant
pathway. Eur J Cell Biol 83:469–76
Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899–912
Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I et al.
(2005) Metastasis-associated protein S100A4 induces angiogenesis
through interaction with Annexin II and accelerated plasmin formation.
J Biol Chem 280:20833–41
Stancato LF, Sakatsume M, David M, Dent P, Dong F, Petricoin EF et al.
(1997) Beta interferon and oncostatin M activate Raf-1 and mitogen-
activated protein kinase through a JAK1-dependent pathway. Mol Cell
Biol 17:3833–40
Strober BE (2005) The treatment of psoriasis with etanercept. Semin Cutan
Med Surg 24:28–36
2656 Journal of Investigative Dermatology (2006), Volume 126
A Gazel et al.
Effects of OsM in Skin Equivalents
Yin T, Green KJ, Getsios S, Huen AC, Ishii K, Gaudry CA et al. (2004)
Regulation of desmosome assembly and adhesion. Semin Cell Dev Biol
15:665–77
Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ
(1986) Oncostatin M: a growth regulator produced by differentiated
histiocytic lymphoma cells. Proc Natl Acad Sci USA 83:9739–43
Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D et al. (2005)
Psoriasis-like skin disease and arthritis caused by inducible epidermal
deletion of Jun proteins. Nature 437:369–75
Zhao XP, Elder JT (1997) Positional cloning of novel skin-specific genes
from the human epidermal differentiation complex. Genomics 45:
250–8
www.jidonline.org 2657
A Gazel et al.
Effects of OsM in Skin Equivalents
